Montgomery Jana E, Brown Jeremiah R
Dartmouth-Hitchcock Medical Center, Division of Cardiology, Lebanon, NH 03756, USA.
Vasc Health Risk Manag. 2013;9:37-45. doi: 10.2147/VHRM.S30378. Epub 2013 Jan 29.
Cardiac and peripheral vascular biomarkers are increasingly becoming targets of both research and clinical practice. As of 2008, cardiovascular-related medical care accounts for greater than 20% of all the economic costs of illness in the United States. In the age of burgeoning financial pressures on the entire health care system, never has it been more important to try to understand who is at risk for cardiovascular disease in order to prevent new events. In this paper, we will discuss the cost of cardiovascular disease to society, clarify the definition of and need for biomarkers, offer an example of a current biomarker, namely high-sensitivity C-reactive protein, and finally examine the approval process for utilizing these in clinical practice.
心脏和外周血管生物标志物日益成为研究和临床实践的目标。截至2008年，在美国，心血管相关医疗保健费用占所有疾病经济成本的20%以上。在整个医疗保健系统面临日益增长的财务压力的时代，了解谁有患心血管疾病的风险以预防新发病例变得前所未有的重要。在本文中，我们将讨论心血管疾病对社会造成的成本，阐明生物标志物的定义和需求，给出一种当前生物标志物即高敏C反应蛋白的示例，最后审视将这些生物标志物用于临床实践的审批过程。
